Vedolizumab-related arthralgias in patients with inflammatory bowel disease

Vedolizumab-related arthralgias in patients with inflammatory bowel disease

Vedolizumab-related arthralgias in patients with inflammatory bowel disease.

מרצים

Dr. Jennifer Ben-Shimol

Clinical Rheumatology specialist.

Edith Wolfson Medical Center

מאמרים רלבנטיים

הפנייה למאמרים המוזכרים בהרצאה.

1. Aghazadeh R et al. J Gastroenterol Hepatol. 2005;20:1691–1695.
2. Levine JS, et al. Gastroenterol Hepatol (N Y). 2011;7(4):235-241.
3. Herrlinger KR,et al. Am J Gastroenterol. 2002 Feb;97(2):377-81.
4. Arvikar SL et al. Curr Rev Musculoskelet Med. 2011;4(3):123-131.
5. Orchard TR, et al. Gut. 1998 Mar;42(3):387-91.
6. Hedin CRH et al. J Crohns Colitis. 2019 Apr 26;13(5):541-554.
7. Singh S, Murad MH, Fumery M, et al Clin Gastroenterol Hepatol. 2020;18:2179–91e6.
8. Singh S, Fumery M, Sandborn WJ, et al. Aliment Pharmacol Ther. 2018;48:394–409.
9. Vavricka SR et al. Inflamm Bowel Dis. 2017 Jul;23(7):1174-1181.
10. Guillo L et al. J Crohns Colitis. 2020 Dec 24:jjaa260.
11. Rubin D et al. The American Journal of Gastroenterology: December 2019 – Volume 114 – Issue – p S21.
12. Scribano ML. World J Gastroenterol 2018; 24(23): 2457-2467.
13. Christensen B, et al. Inflamm Bowel Dis. 2018; 24: 849-860.
14. Buer LCT, et al. Scand J Gastroenterol. 2019; 54: 41-8.
15. Baumgart DC et al. Aliment Pharmacol Ther. 2016; 43:1090-102.
16. Biemans VBC et al. Clin Pharmacol Ther. 2020; 107:1189-99. Parikh A et al. Inflamm Bowel Dis. 2011; 17(suppl_1): S56-S56.
17. Löwenberg M et al. Gastroenterology. 2019; 157:997-1006.e6.
18. Shelton E et al. Inflamm Bowel Dis. 2015; 21: 2879-85.
19. Wendling D et al. Joint Bone Spine 2018; 85: 255-6.
20. Dubash S et al. Rheumatology (Oxford). 2019; 58: 963-8. Varkas G et al. Ann Rheum Dis. 2017; 76: 878–81.
21. Dupré A et al. Rheumatology (Oxford). 2020; 59: 3275-83.
22. Reinglas J et al. Dig Dis Sci. 2020; 65: 2046-53. Macaluso FS et al. Dig Liver Dis. 2018;50: 675-81.
23. Fleisher M et al. Dig Dis Sci. 2018; 63: 825-33. Danese S et al. Gastroenterology. 2019; 157:1007-18.e7.
24. Tadbiri S et al. Aliment Pharmacol Ther. 2018; 47: 485-93.
25. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005 Jun 16;352(24):2499-507.
26. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699-710.
27. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013 Aug 22;369(8):711-21.
28. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D’Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep;147(3):618-627.e3.
29. Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019 Feb 26;14(2):e0212989.
30. Feagan BG et al. J Crohns Colitis. 2019; 13: 50-57.
31. Mayo Clinic. “Digestive diseases.” Accessed 29.3.21

RHEUMATOLOGY, IBD, גסטרואנטרולוגיה, הרצאות-מצולמות